Skip to main content
EXACT Therapeutics AS logo

EXACT Therapeutics AS — Investor Relations & Filings

Ticker · EXTX ISIN · NO0010852213 LEI · 2138006ZE5JAL39AGD55 OL Manufacturing
Open in API
Filings indexed 233 across all filing types
Latest filing 2025-07-08 Regulatory Filings
Country NO Norway
Listing OL EXTX

About EXACT Therapeutics AS

https://www.exact-tx.com/

EXACT Therapeutics AS is a clinical-stage biopharmaceutical company developing its proprietary technology platform, Acoustic Cluster Therapy (ACT®), for targeted therapeutic enhancement. The ACT® platform uses ultrasound to amplify the effect of co-administered drugs, with a primary focus on oncology. Its biomechanical mode of action increases the local uptake of therapeutics from blood vessels into the surrounding tissue, including across the blood-brain barrier, without requiring drug reformulation. This non-invasive technology is designed to be compatible with standard ultrasound systems. The company's pipeline includes the ENACT study, a Phase 2 trial evaluating ACT® in patients with locally advanced pancreatic cancer, following the completion of the ACTIVATE Phase 1 study in patients with liver metastases.

Recent filings

Filing Released Lang Actions
EXACT Therapeutics announces grant of core patent in the U.S.
Regulatory Filings Classification · 95% confidence The document is a short press release announcing that EXACT Therapeutics has been granted a core patent (U.S. Patent No. 12,343,396) by the USPTO. This announcement relates to intellectual property and technological development, which is a specific type of corporate update. It is not a full financial report (10-K, IR), an earnings release (ER), a management discussion (MDA), or a dividend notice (DIV). Since there is no specific category for 'Patent Grant Announcement,' and it is a material corporate event announcement, it fits best under the general 'Regulatory Filings' (RNS) category, which serves as a fallback for significant, non-standard announcements. Given the short length and nature, it is not an Investor Presentation (IP) or a Fund Factsheet (FS).
2025-07-08 English
EXACT Therapeutics announces first patient dosed in Phase 2 trial in patients with locally advanced pancreatic cancer
Regulatory Filings Classification · 95% confidence The document is a press release announcing a specific operational milestone: dosing the first patient in a Phase 2 clinical trial for pancreatic cancer. This type of announcement, detailing clinical progress, is typically classified as a general regulatory announcement or news release, as it does not fit neatly into the specific financial report categories (like 10-K, ER, IR) or corporate governance categories. Given the options, 'Regulatory Filings' (RNS) serves as the best general category for significant, non-financial, operational news releases that are often filed with exchanges or regulators for public dissemination. The document length is short (2886 chars), but it is the primary content, not an announcement *about* another report, so RPA is not appropriate. It is not a Director's Dealing, Capital Change, or Earnings Release.
2025-06-24 English
EXACT Therapeutics AS: Primary insider notification - Attachment: Notification of transactions by Primary Insiders (grant options).pdf
Director's Dealing Classification · 100% confidence The document is explicitly titled "Notification of transactions by Primary Insiders and Close Associates". It details a transaction involving a 'Board member' (Jonathan Allis) of the issuer (EXACT Therapeutics AS). Specifically, it records the 'Grant of share option'. This type of filing, reporting personal share transactions by company directors and executives (insider trades), directly corresponds to the definition of Director's Dealing.
2025-06-13 English
EXACT Therapeutics AS: Primary insider notification
Board/Management Information Classification · 99% confidence The document explicitly states it is a 'Primary insider notification' concerning the re-election of a director (Jonathan Allis) and the subsequent granting of stock options to him. This directly relates to transactions by company directors/executives. This aligns perfectly with the definition of Director's Dealing (DIRS), which covers reports of personal share transactions by company directors and executives (insider trades). The document is short and references an attached notification form, but the core content is the insider transaction disclosure itself, making DIRS a more specific fit than RPA or RNS.
2025-06-13 English
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025 - Attachment: 20250613_EXACT_Therapeutics_AS_AGM.pdf
AGM Information Classification · 100% confidence The document is explicitly titled "PROTOKOLL FRA ORDINÆR GENERALFORSAMLING" (Minutes of Annual General Meeting) in both Norwegian and English. It details the proceedings, resolutions passed (approval of financial statements, election of board members, approval of remuneration, and authorization for capital increases), and the date of the meeting (June 13, 2025). This content perfectly matches the definition of an Annual General Meeting document, specifically the official minutes recording the outcomes. Therefore, the classification is AGM-R.
2025-06-13 Norwegian
EXACT Therapeutics minutes from Annual General Meeting June 13, 2025
AGM Information Classification · 99% confidence The document explicitly states it contains the "minutes from Annual General Meeting June 13, 2025". This directly corresponds to the definition of AGM Information (Code: AGM-R), which covers presentations and materials shared during the Annual General Meeting (AGM). Although it mentions 'minutes' and 'enclosed', the core subject matter is the AGM proceedings, making AGM-R the most specific fit over a general Report Publication Announcement (RPA). The document length is short, but the content is the official record of the AGM.
2025-06-13 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.